Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular failure with labetalol.

M A Frais, T J Bayley

    Postgraduate Medical Journal
    |September 1, 1979
    PubMed
    Summary

    Labetalol, used for hypertension, can cause heart failure due to its stronger beta-blocking effects. Discontinuing labetalol and managing blood pressure with other agents led to symptom regression, highlighting the need for caution in at-risk patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    GIM and specialty medicine.

    Journal of the Royal College of Physicians of London·2000
    Same author

    Postgraduate deans will deal with accusations of fraud.

    BMJ (Clinical research ed.)·1995
    Same author

    Unified training grade.

    BMJ (Clinical research ed.)·1995
    Same author

    Specialist training.

    Medical education·1995
    Same author

    The hospital component of vocational training for general practice.

    BMJ (Clinical research ed.)·1994
    Same author

    Specialist medical training: implementing Calman: summing up.

    Medical education·1994

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Hypertension management often involves medications with varying mechanisms.
    • Labetalol is a dual-acting antihypertensive agent with both alpha- and beta-blocking properties.

    Observation:

    • A patient receiving labetalol for hypertension developed signs of left ventricular failure.
    • The patient's cardiac symptoms improved after labetalol was discontinued.
    • Blood pressure was effectively managed using alternative antihypertensive agents.

    Findings:

    • The adverse cardiac event was potentially linked to the pronounced beta-blocking activity of labetalol compared to its alpha-blocking effects.
    • Withdrawal of labetalol resulted in the regression of heart failure symptoms.

    Implications:

    • Clinicians should exercise caution when prescribing labetalol to patients with pre-existing or symptomatic heart failure.
    • The balance of alpha- and beta-adrenergic blockade in labetalol necessitates careful patient selection, particularly in those with compromised cardiac function.

    Related Experiment Videos